{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:34:51Z","timestamp":1780342491649,"version":"3.54.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/internalmedicine.52.0696","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T22:43:10Z","timestamp":1387060990000},"page":"2707-2713","source":"Crossref","is-referenced-by-count":10,"title":["Low-density Lipoprotein Cholesterol is a Predictor of Metabolic Syndrome in a Japanese Health Screening Population"],"prefix":"10.2169","volume":"52","author":[{"given":"Eiji","family":"Oda","sequence":"first","affiliation":[{"name":"Medical Check-up Center, Tachikawa Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 49: 89-95, 2012."},{"key":"2","unstructured":"2. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO Consultation. World Health Organization, Geneva, 1999."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.","DOI":"10.1001\/jama.285.19.2486"},{"key":"4","unstructured":"4. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23: 469-480, 2006."},{"key":"5","unstructured":"5. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752, 2005."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645, 2009.","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"7","unstructured":"7. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289-2304, 2005."},{"key":"8","unstructured":"8. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53: 600-605, 2010."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 31: 1283-1291, 2008.","DOI":"10.1291\/hypres.31.1283"},{"key":"10","unstructured":"10. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46: 2347-2355, 2005.","DOI":"10.1194\/jlr.M500294-JLR200"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ridker PM, Wilson PWF, Grandy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109: 2818-2825, 2004.","DOI":"10.1161\/01.CIR.0000132467.45278.59"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Reaven GM. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.","DOI":"10.2337\/diab.37.12.1595"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113: 1888-1904, 2006.","DOI":"10.1161\/CIRCULATIONAHA.105.563213"},{"key":"15","unstructured":"15. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 90: 1056-1069, 1994."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism 29: 1053-1060, 1980.","DOI":"10.1016\/0026-0495(80)90216-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. The Examination Committee for Criteria of Metabolic Syndrome. Definition and criteria of metabolic syndrome. J Jpn Soc Intern Med 94: 794-809, 2005 (in Japanese).","DOI":"10.2169\/naika.94.794"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. McNeely MJ, Shofer JB, Leonetti DL, et al. Associations among visceral fat, all-cause mortality, and obesity-related mortality in Japanese Americans. Diabetes Care 35: 296-298, 2012.","DOI":"10.2337\/dc11-1193"},{"key":"19","unstructured":"19. Herrera MF, Pantoja JP, Velázquez-Fernández D, et al. Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: a randomized trial. Diabetes Care 33: 1413-1418, 2010."},{"key":"20","unstructured":"20. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126, 1999."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 108: 2312-2316, 2003.","DOI":"10.1161\/01.CIR.0000097113.11419.9E"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Onat A, Can G, Hergenç G, Yazici M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes 31: 1119-1125, 2007.","DOI":"10.1038\/sj.ijo.0803552"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Holvoet P, Lee D-H, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299: 2287-2293, 2008.","DOI":"10.1001\/jama.299.19.2287"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/24\/52_52.0696\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:47:18Z","timestamp":1621446438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/24\/52_52.0696\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":23,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.52.0696","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}